How Does Lagevrio Work? Mechanism of Action Explained in Plain English

Lagevrio (molnupiravir) works in a fundamentally different way from Paxlovid and Remdesivir. Instead of blocking a viral enzyme, it attacks the virus at the genetic level — introducing so many errors into the virus's copying process that it can no longer reproduce. Here's how it actually works.

Understanding How SARS-CoV-2 Replicates

To understand how Lagevrio works, it helps to understand what it's fighting. SARS-CoV-2, like all coronaviruses, is an RNA virus. Its genetic instructions are written in RNA (ribonucleic acid) rather than DNA. When the virus infects a cell, it uses a protein called RNA-dependent RNA polymerase (RdRp) to copy its RNA genome and make new virus particles. The more copies it makes, the more cells it infects, and the worse the illness becomes.

Step 1: Molnupiravir Enters the Body as a Prodrug

Molnupiravir is a prodrug — meaning it's not active in its original form. After you swallow it, enzymes in your bloodstream (esterases) rapidly convert molnupiravir into its active form: N4-hydroxycytidine, or NHC. NHC looks very similar to cytidine, one of the natural building blocks of RNA.

Step 2: NHC Gets Activated Inside Infected Cells

Once NHC enters cells infected by SARS-CoV-2, it undergoes further chemical modification — being phosphorylated into its pharmacologically active form, NHC triphosphate (NHC-TP). This activated form is now ready to interfere with the virus's copying machinery.

Step 3: The Virus Mistakes NHC for a Real RNA Building Block

Here's where the magic happens. When the SARS-CoV-2 RdRp enzyme starts copying the viral RNA genome, it encounters NHC-TP. Because NHC looks so similar to the natural building blocks, the enzyme picks it up and incorporates it into the new RNA chain — as if it were a normal nucleotide.

But NHC is a trickster. Unlike normal cytidine, NHC can pair with either guanine OR adenine during the copying process. This means that every time NHC is incorporated, there's a chance it will cause the wrong base to be added to the opposite RNA strand in the next copying round.

Step 4: Errors Accumulate — Viral Error Catastrophe

Each incorporation of NHC causes a mutation in the viral genome. As the virus copies itself again and again — incorporating NHC multiple times — mutations pile up across the viral RNA. This process is called 'viral error catastrophe' or 'viral lethal mutagenesis.' The virus accumulates so many genetic errors that it produces non-functional copies that cannot infect new cells or replicate further.

Think of it this way: if you're making photocopies of a document, and each copy introduces random errors, after enough rounds of copying, the document becomes complete gibberish. That's essentially what Lagevrio does to the SARS-CoV-2 genome.

How Is This Different from Paxlovid?

Paxlovid (nirmatrelvir/ritonavir) works by blocking the SARS-CoV-2 main protease (Mpro), an enzyme the virus needs to process its proteins into functional components. Think of Paxlovid as locking a door — the virus can't assemble itself properly. Lagevrio, by contrast, lets the virus try to copy itself but sabotages the copies so they don't work.

Because Lagevrio works at the genetic level rather than on a protein target, it does not have the same drug interaction profile as Paxlovid. This is why it's the preferred option for patients on medications that interact with ritonavir.

Why the Concern About DNA Mutations?

A legitimate scientific question is whether NHC could be incorporated into human DNA as well as viral RNA — potentially causing mutations in the patient's own cells. This theoretical risk is one reason Lagevrio is not recommended in pregnancy (where fetal cells are rapidly dividing) and not authorized for patients under 18. Current evidence suggests this risk is low at therapeutic doses over 5 days, but it's an important consideration in prescribing decisions.

Why Must Lagevrio Be Started Early?

Lagevrio's mechanism works best when viral replication is still in its early stages. Once the virus has replicated extensively and the immune system's inflammatory response is the primary driver of severe disease (later stages), antiviral treatment has much less impact. This is why the EUA requires treatment to start within 5 days of symptom onset — the earlier, the better.

For a full overview of Lagevrio including dosing and who it's for, see our Lagevrio overview guide.

If you've been prescribed Lagevrio and need to find a pharmacy with it in stock, medfinder can help you locate one near you quickly.